The submissions are supported by data from the Phase 3 KEYNOTE-905 trial
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
The company has been entrusted with the responsibility of supplying a wide range of essential oncology drugs
Pemetrexed Injection is used as a drug, in the treatment of non-small cell lung cancer in combination with other chemotherapy agents
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Venus Remedies' oncology wing has also secured marketing authorisation from Myanmar for another chemotherapy drug
Shilpa Medicare Limited is the first company to receive approval for Manufacturing & Market of Pemetrexed Injection 10 ml, 50 ml, 85 ml, and 100 ml in India
The company expects this approval in Baddi to pave the way for GMP certifications from European Medicines Agency and other PIC/S member nations
Subscribe To Our Newsletter & Stay Updated
